MoonLake Immunotherapeutics (MLTX) Cash from Operations (2021 - 2026)

MoonLake Immunotherapeutics' Cash from Operations history runs 6 years deep, the most recent figure standing at 66286000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 73.8% year-over-year to 66286000.0; the TTM figure through Mar 2026 stood at 224153000.0 (down 60.36% YoY), while the FY2025 annual figure was 196007000.0, down 68.12% from the prior year.
• Cash from Operations was 66286000.0 for Q1 2026 at MoonLake Immunotherapeutics, down from 58794000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 9024427.0 in Q1 2023 to a low of 66286000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 28091288.24 across 5 years, with a median of 20760383.0 in 2022.
• Biggest YoY gain for Cash from Operations was 67.03% in 2022; the steepest drop was 13060.13% in 2022.
• A 5-year view of Cash from Operations shows it stood at 11595982.0 in 2022, then fell by 6.45% to 12344159.0 in 2023, then tumbled by 292.68% to 48473000.0 in 2024, then retreated by 21.29% to 58794000.0 in 2025, then declined by 12.74% to 66286000.0 in 2026.
• The last three Cash from Operations figures came in at 66286000.0 (Q1 2026), 58794000.0 (Q4 2025), and 44543000.0 (Q3 2025), per Business Quant data.